Monopar Therapeutics logo
Monopar Therapeutics
MNPR | NASDAQ
Chart Builder DCF Calculator
$71.97
-$0.03 (-0.04%)
At close: Nov 16, 2026, 4:00 PM ET
$71.97
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Monopar Therapeutics Company Profile

Company profile explained

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Key Executives

Name Position
Chandler D. Robinson Co-Founder, Chief Executive Officer, President & Director
Andrew J. Cittadine Chief Operating Officer
Christopher Starr Co-Founder & Independent Executive Chairman of the Board
Jeffrey D. Kent FACG FACP Executive Vice President of Head of Medical Affairs
Patrice Rioux Acting Chief Medical Officer
Quan Anh Vu CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer
Susan Rodriguez Chief Commercial & Strategy Officer

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 20, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 28, 2026 4 Filing
Aug 28, 2026 4/A [Amend] Filing
Aug 28, 2026 4/A [Amend] Filing
Aug 27, 2026 4 Filing
View All SEC Filings ➞
Monopar Therapeutics
Monopar Therapeutics logo
Country United States
IPO Date Dec 19, 2019
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Chandler D. Robinson

Contact Details

1000 Skokie Boulevard Wilmette, Illinois 60091 United States

Stock Details

Ticker Symbol MNPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645469
CUSIP Number 61023L207
ISIN Number US61023L2079
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.